ZA200102033B - Arylsulfonanilide ureas. - Google Patents

Arylsulfonanilide ureas. Download PDF

Info

Publication number: ZA200102033B
Authority: ZA; South Africa
Prior art keywords: group; compound; hydrogen; alkyl; heteroalkyl
Prior art date: 1998-09-23

Application number

ZA200102033A

Other languages

English (en)

Inventor

Jonathan B Houze

Original Assignee

Tularik Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-23

Filing date

1999-09-21

Publication date

2001-09-12

1999-09-21 Application filed by Tularik Inc filed Critical Tularik Inc

2001-09-12 Publication of ZA200102033B publication Critical patent/ZA200102033B/en

Links

150000003672 ureas Chemical class 0.000 title description 4
235000013877 carbamide Nutrition 0.000 title description 3
-1 1,2,3,4-tetrazolyl Chemical group 0.000 claims description 45
150000001875 compounds Chemical class 0.000 claims description 42
125000000217 alkyl group Chemical group 0.000 claims description 38
125000004404 heteroalkyl group Chemical group 0.000 claims description 38
229910052739 hydrogen Inorganic materials 0.000 claims description 35
239000001257 hydrogen Substances 0.000 claims description 34
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 20
125000003118 aryl group Chemical group 0.000 claims description 20
125000000623 heterocyclic group Chemical group 0.000 claims description 18
239000000203 mixture Substances 0.000 claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
201000010099 disease Diseases 0.000 claims description 12
229910052757 nitrogen Inorganic materials 0.000 claims description 12
150000002431 hydrogen Chemical class 0.000 claims description 11
206010028980 Neoplasm Diseases 0.000 claims description 10
125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 9
201000004681 Psoriasis Diseases 0.000 claims description 8
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
229910052760 oxygen Inorganic materials 0.000 claims description 8
229910052717 sulfur Inorganic materials 0.000 claims description 8
201000011510 cancer Diseases 0.000 claims description 7
230000004663 cell proliferation Effects 0.000 claims description 7
238000000034 method Methods 0.000 claims description 7
230000002062 proliferating effect Effects 0.000 claims description 7
125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 6
125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 6
229910052794 bromium Inorganic materials 0.000 claims description 6
229910052801 chlorine Inorganic materials 0.000 claims description 6
229910052731 fluorine Inorganic materials 0.000 claims description 6
229910052736 halogen Inorganic materials 0.000 claims description 6
150000002367 halogens Chemical class 0.000 claims description 6
239000003795 chemical substances by application Substances 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
208000035150 Hypercholesterolemia Diseases 0.000 claims description 3
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
208000015181 infectious disease Diseases 0.000 claims description 3
229960000485 methotrexate Drugs 0.000 claims description 3
208000037803 restenosis Diseases 0.000 claims description 3
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims description 2
229930012538 Paclitaxel Natural products 0.000 claims description 2
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
230000001028 anti-proliverative effect Effects 0.000 claims description 2
229960004316 cisplatin Drugs 0.000 claims description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
229960004397 cyclophosphamide Drugs 0.000 claims description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
229960002074 flutamide Drugs 0.000 claims description 2
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 2
229960001592 paclitaxel Drugs 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
229960001603 tamoxifen Drugs 0.000 claims description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
125000005309 thioalkoxy group Chemical group 0.000 claims description 2
230000002792 vascular Effects 0.000 claims description 2
229960003048 vinblastine Drugs 0.000 claims description 2
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
229960004528 vincristine Drugs 0.000 claims description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 3
125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 claims 3
102000007330 LDL Lipoproteins Human genes 0.000 claims 2
108010007622 LDL Lipoproteins Proteins 0.000 claims 2
239000008280 blood Substances 0.000 claims 2
210000004369 blood Anatomy 0.000 claims 2
235000012000 cholesterol Nutrition 0.000 claims 2
239000002245 particle Substances 0.000 claims 2
125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims 1
125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims 1
125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims 1
125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 claims 1
102000004895 Lipoproteins Human genes 0.000 claims 1
108090001030 Lipoproteins Proteins 0.000 claims 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
239000003529 anticholesteremic agent Substances 0.000 claims 1
239000003524 antilipemic agent Substances 0.000 claims 1
229960003668 docetaxel Drugs 0.000 claims 1
230000000871 hypocholesterolemic effect Effects 0.000 claims 1
125000002883 imidazolyl group Chemical group 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
244000005700 microbiome Species 0.000 claims 1
125000002971 oxazolyl group Chemical group 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
125000003226 pyrazolyl group Chemical group 0.000 claims 1
125000000565 sulfonamide group Chemical group 0.000 claims 1
125000000335 thiazolyl group Chemical group 0.000 claims 1
125000005842 heteroatom Chemical group 0.000 description 9
210000004027 cell Anatomy 0.000 description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
125000004432 carbon atom Chemical group C* 0.000 description 6
125000002947 alkylene group Chemical group 0.000 description 5
125000001424 substituent group Chemical group 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
125000004474 heteroalkylene group Chemical group 0.000 description 4
125000000592 heterocycloalkyl group Chemical group 0.000 description 4
150000003254 radicals Chemical class 0.000 description 4
125000004434 sulfur atom Chemical group 0.000 description 4
208000035143 Bacterial infection Diseases 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
208000022362 bacterial infectious disease Diseases 0.000 description 3
125000000753 cycloalkyl group Chemical group 0.000 description 3
125000001072 heteroaryl group Chemical group 0.000 description 3
125000005647 linker group Chemical group 0.000 description 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
102000029749 Microtubule Human genes 0.000 description 2
108091022875 Microtubule Proteins 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000000340 anti-metabolite Effects 0.000 description 2
229940100197 antimetabolite Drugs 0.000 description 2
239000002256 antimetabolite Substances 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
210000004688 microtubule Anatomy 0.000 description 2
125000004430 oxygen atom Chemical group O* 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
208000017520 skin disease Diseases 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
231100001274 therapeutic index Toxicity 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
125000004417 unsaturated alkyl group Chemical group 0.000 description 2
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
239000012624 DNA alkylating agent Substances 0.000 description 1
239000012625 DNA intercalator Substances 0.000 description 1
229940122029 DNA synthesis inhibitor Drugs 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
229940123414 Folate antagonist Drugs 0.000 description 1
241000233866 Fungi Species 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
229910003849 O-Si Inorganic materials 0.000 description 1
229910003872 O—Si Inorganic materials 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
206010034133 Pathogen resistance Diseases 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
206010037575 Pustular psoriasis Diseases 0.000 description 1
229910007161 Si(CH3)3 Inorganic materials 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000005165 aryl thioxy group Chemical group 0.000 description 1
125000004104 aryloxy group Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
210000001217 buttock Anatomy 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
210000004413 cardiac myocyte Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
229940079593 drug Drugs 0.000 description 1
210000001513 elbow Anatomy 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
210000004709 eyebrow Anatomy 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
239000004052 folic acid antagonist Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
210000003904 glomerular cell Anatomy 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
238000001794 hormone therapy Methods 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
208000020346 hyperlipoproteinemia Diseases 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
150000002611 lead compounds Chemical class 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
210000000282 nail Anatomy 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229960003552 other antineoplastic agent in atc Drugs 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001185 psoriatic effect Effects 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
239000003790 pyrimidine antagonist Substances 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
210000004761 scalp Anatomy 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
Separation Of Suspended Particles By Flocculating Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Thiazole And Isothizaole Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Furan Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)
Pyrrole Compounds (AREA)

ZA200102033A 1998-09-23 1999-09-21 Arylsulfonanilide ureas. ZA200102033B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10088898P	1998-09-23	1998-09-23

Publications (1)

Publication Number	Publication Date
ZA200102033B true ZA200102033B (en)	2001-09-12

Family

ID=22282047

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200102033A ZA200102033B (en)	1998-09-23	1999-09-21	Arylsulfonanilide ureas.

Country Status (24)

Country	Link
US (3)	US6214880B1 (cs)
EP (1)	EP1115701B1 (cs)
JP (1)	JP3926983B2 (cs)
KR (1)	KR100642184B1 (cs)
CN (1)	CN100335461C (cs)
AT (1)	ATE240940T1 (cs)
AU (1)	AU747663B2 (cs)
BR (1)	BR9913903A (cs)
CA (1)	CA2343204C (cs)
CZ (1)	CZ2001934A3 (cs)
DE (1)	DE69908156T2 (cs)
DK (1)	DK1115701T3 (cs)
EA (1)	EA003924B1 (cs)
ES (1)	ES2194547T3 (cs)
HK (1)	HK1038913A1 (cs)
HU (1)	HUP0103884A3 (cs)
IL (2)	IL142066A0 (cs)
NO (1)	NO20011453L (cs)
NZ (1)	NZ510435A (cs)
PL (1)	PL198394B1 (cs)
PT (1)	PT1115701E (cs)
SK (1)	SK284757B6 (cs)
WO (1)	WO2000017159A1 (cs)
ZA (1)	ZA200102033B (cs)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9508644D0 (en) *	1995-04-28	1995-06-14	Exxon Chemical Patents Inc	Fuel compositions
SK284757B6 (sk) *	1998-09-23	2005-11-03	Tularik Inc.	Arylsulfónanilidmočoviny, farmaceutický prostriedok s ich obsahom a ich použitie
US6316503B1 (en) *	1999-03-15	2001-11-13	Tularik Inc.	LXR modulators
DK1206256T3 (da) *	1999-07-29	2005-08-15	Amgen Inc	Kombinationsbehandling under anvendelse af pentafluorbenzensulfonamid og platinforbindelse
CO5280089A1 (es) *	2000-03-16	2003-05-30	Smithkline Beecham Corp	Antagonistas del receptor il-8
US6664259B2 (en)	2000-03-16	2003-12-16	Smithkline Beecham Corporation	Il-8 receptor antagonists
UY26627A1 (es) *	2000-03-24	2001-09-28	Smithkline Beecham Corp	Antagonistas de receptores de il-8
WO2002020463A2 (en) *	2000-09-05	2002-03-14	Tularik Inc.	Fxr modulators
US20050250854A1 (en) *	2000-11-03	2005-11-10	Amgen Inc.	Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
WO2002039958A2 (en)	2000-11-03	2002-05-23	Tularik Inc.	Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US6646009B2 (en)	2001-02-28	2003-11-11	Temple University — Of Commonwealth System of Higher Education	N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
AUPR738301A0 (en) *	2001-08-30	2001-09-20	Starpharma Limited	Chemotherapeutic agents
WO2003063796A2 (en) *	2002-01-30	2003-08-07	Tularik Inc.	Heterocyclic arylsulfonamidobenzylic compounds
WO2003063576A2 (en) *	2002-01-30	2003-08-07	Tularik Inc.	Arylsulfonamidobenzylic compounds
ATE517626T1 (de)	2002-02-28	2011-08-15	Univ Temple	Aminosubstituierte sulphonanilide und ihre derivate zur behandlung von proliferativen erkrankungen
AR041834A1 (es) *	2002-10-29	2005-06-01	Smithkline Beecham Corp	Compuesto de difenilurea sustituido con sulfonamida, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
WO2005016277A2 (en) *	2003-08-12	2005-02-24	Amgen Inc.	Arylsulfonamidobenzylic compounds
US20050124664A1 (en) *	2003-10-30	2005-06-09	Eric Sartori	Urea thiadiazole inhibitors of plasminogen activator inhibior-1
US20050154455A1 (en) *	2003-12-18	2005-07-14	Medtronic Vascular, Inc.	Medical devices to treat or inhibit restenosis
US20050261762A1 (en) *	2004-05-21	2005-11-24	Medtronic Vascular, Inc.	Medical devices to prevent or inhibit restenosis
US20060062822A1 (en) *	2004-09-21	2006-03-23	Medtronic Vascular, Inc.	Medical devices to treat or inhibit restenosis
US20070027530A1 (en) *	2005-07-26	2007-02-01	Medtronic Vascular, Inc.	Intraluminal device, catheter assembly, and method of use thereof
FI20055498A0 (fi) *	2005-09-16	2005-09-16	Biotie Therapies Corp	Sulfonamidijohdannaisia
US20070067020A1 (en) *	2005-09-22	2007-03-22	Medtronic Vasular, Inc.	Intraluminal stent, delivery system, and a method of treating a vascular condition
CA2650007A1 (en) *	2006-04-21	2007-11-01	Smithkline Beecham Corporation	Il-8 receptor antagonists
MX2008013600A (es) *	2006-04-21	2008-10-31	Smithkline Beechman Corp	Antagonistas del receptor de interleuquina-8.
WO2007139930A2 (en) *	2006-05-26	2007-12-06	Bayer Healthcare Llc	Drug combinations with substituted diaryl ureas for the treatment of cancer
PE20080943A1 (es) *	2006-06-23	2008-09-27	Smithkline Beecham Corp	Sal toluenosulfonato de 4-{[6-cloro-3-({[(2-cloro-3-fluorofenil)amino]carbonil}amino)-2-hidroxifenil]sulfonil}-1-piperazinacarboxilato de 1,1-dimetiletilo como antagonista del receptor de il-8
AU2008347024A1 (en) *	2007-10-19	2009-07-16	Omm Scientific, Inc.	Methods of inhibiting bacterial virulence and compounds relating thereto
EP2385831A4 (en) *	2009-01-09	2014-03-26	Uab Research Foundation	SMALL MOLECULAR HEMMER OF NADS, NAMNAT AND NMNAT
BR112015011253B1 (pt)	2012-11-21	2021-11-09	Nippon Soda Co., Ltd	Material de gravação, folha de gravação, método para uso de um composto
US9444712B2 (en)	2012-11-21	2016-09-13	Cisco Technology, Inc.	Bandwidth on-demand services in multiple layer networks
JPWO2017170826A1 (ja) *	2016-03-30	2019-02-14	味の素株式会社	グルカゴン様ペプチド−１受容体作用増強活性を有する化合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1955207A (en)	1931-09-16	1934-04-17	Ig Farbenindustrie Ag	Mothproofing agent
DE622494C (de)	1932-01-03	1935-11-29	I G Farbenindustrie Akt Ges	Verfahren zur Darstellung von Mono- bzw. Polynitropolysulfonen und deren Reduktionsprodukten
US2358365A (en)	1940-08-03	1944-09-19	Parke Davis & Co	Sulphonamide derivatives and process for obtaining the same
US2402623A (en)	1943-06-24	1946-06-25	Rohm & Haas	Nu-nitroaryl haloarylsulphonamides
CH362688A (de)	1957-09-10	1962-06-30	Geigy Ag J R	Verfahren zur Herstellung von neuen Arylsulfonarylamiden
GB938890A (en)	1961-02-03	1963-10-09	Boots Pure Drug Co Ltd	New fungicidal compositions and compounds
CH504416A (de)	1966-12-05	1971-03-15	Ciba Geigy Ag	Verfahren zur Herstellung von aromatischen Sulfamoylverbindungen
GB1242057A (en)	1968-07-04	1971-08-11	Ici Ltd	Derivatives of 4-hydroxytetrafluoropyridine and the use thereof as plant growth regulators
NL174644C (nl)	1970-04-13	1984-07-16	Minnesota Mining & Mfg	Werkwijze ter bereiding van een herbicide verbinding; tevens werkwijze voor de bereiding van een preparaat met herbicide werking.
FR2456731A1 (fr) *	1979-05-16	1980-12-12	Choay Sa	Nouveaux derives substitues d'ary
DE3623184A1 (de)	1986-07-10	1988-01-14	Kali Chemie Ag	Verfahren zur herstellung von n-fluorsulfonamiden
US4883914A (en)	1987-08-17	1989-11-28	American Cyanamid Company	Benzenesulfonyl carboxamide compounds useful as herbicidal agents
DE3804990A1 (de)	1988-02-18	1989-08-31	Basf Ag	Herbizid wirksame, heterocyclisch substituierte sulfonamide
DE3905075A1 (de)	1989-02-18	1990-08-30	Hoechst Ag	Benzolsulfonamide und verfahren zu ihrer herstellung
FR2645537B1 (fr)	1989-04-05	1994-03-04	Fabre Medicament Pierre	Nouveaux sulfonamides derives d'acides benzocycliques ou benzoheterocycliques, leur preparation et leur application en therapeutique
FR2665440B1 (fr)	1990-07-31	1994-02-04	Lipha	Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
US5189211A (en)	1990-08-01	1993-02-23	Taisho Pharmaceutical Co., Ltd.	Sulfonamide derivatives
DE69129611T2 (de)	1990-08-20	1998-12-17	Eisai Co., Ltd., Tokio/Tokyo	Sulfonamid-Derivate
US5780483A (en) *	1995-02-17	1998-07-14	Smithkline Beecham Corporation	IL-8 receptor antagonists
DK0896533T3 (da)	1996-02-22	2004-01-26	Tularik Inc	Pentafluorbenzensulfonamider og analoger
IL127965A0 (en)	1996-07-19	1999-11-30	Tularik Inc	Pentafluorobenzenesulfonamide derivatives analogs thereof and pharmaceutical compositions containing the same
AU1208999A (en)	1997-11-10	1999-05-31	Array Biopharma, Inc.	Compounds which inhibit tryptase activity
CA2300197A1 (en)	1997-12-23	1999-07-01	Warner-Lambert Company	Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
SK284757B6 (sk) *	1998-09-23	2005-11-03	Tularik Inc.	Arylsulfónanilidmočoviny, farmaceutický prostriedok s ich obsahom a ich použitie
DK1206256T3 (da) *	1999-07-29	2005-08-15	Amgen Inc	Kombinationsbehandling under anvendelse af pentafluorbenzensulfonamid og platinforbindelse

1999
- 1999-09-21 SK SK400-2001A patent/SK284757B6/sk not_active IP Right Cessation
- 1999-09-21 ZA ZA200102033A patent/ZA200102033B/en unknown
- 1999-09-21 BR BR9913903-0A patent/BR9913903A/pt not_active Application Discontinuation
- 1999-09-21 US US09/399,907 patent/US6214880B1/en not_active Expired - Fee Related
- 1999-09-21 CN CNB99811233XA patent/CN100335461C/zh not_active Expired - Fee Related
- 1999-09-21 AT AT99969408T patent/ATE240940T1/de not_active IP Right Cessation
- 1999-09-21 CZ CZ2001934A patent/CZ2001934A3/cs unknown
- 1999-09-21 PT PT99969408T patent/PT1115701E/pt unknown
- 1999-09-21 PL PL346797A patent/PL198394B1/pl not_active IP Right Cessation
- 1999-09-21 WO PCT/US1999/022013 patent/WO2000017159A1/en active IP Right Grant
- 1999-09-21 EP EP99969408A patent/EP1115701B1/en not_active Expired - Lifetime
- 1999-09-21 HU HU0103884A patent/HUP0103884A3/hu unknown
- 1999-09-21 JP JP2000574069A patent/JP3926983B2/ja not_active Expired - Fee Related
- 1999-09-21 ES ES99969408T patent/ES2194547T3/es not_active Expired - Lifetime
- 1999-09-21 EA EA200100376A patent/EA003924B1/ru not_active IP Right Cessation
- 1999-09-21 KR KR1020017003646A patent/KR100642184B1/ko not_active IP Right Cessation
- 1999-09-21 DE DE69908156T patent/DE69908156T2/de not_active Expired - Fee Related
- 1999-09-21 NZ NZ510435A patent/NZ510435A/xx unknown
- 1999-09-21 DK DK99969408T patent/DK1115701T3/da active
- 1999-09-21 AU AU60580/99A patent/AU747663B2/en not_active Ceased
- 1999-09-21 IL IL14206699A patent/IL142066A0/xx active IP Right Grant
- 1999-09-21 CA CA002343204A patent/CA2343204C/en not_active Expired - Fee Related
2001
- 2001-02-21 US US09/792,669 patent/US6583165B2/en not_active Expired - Fee Related
- 2001-03-18 IL IL142066A patent/IL142066A/en not_active IP Right Cessation
- 2001-03-22 NO NO20011453A patent/NO20011453L/no not_active Application Discontinuation
2002
- 2002-01-17 HK HK02100388A patent/HK1038913A1/xx not_active IP Right Cessation
2003
- 2003-03-11 US US10/387,217 patent/US7060718B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EA003924B1 (ru)	2003-10-30
NZ510435A (en)	2003-04-29
US20030207864A1 (en)	2003-11-06
CZ2001934A3 (cs)	2001-08-15
US7060718B2 (en)	2006-06-13
US6583165B2 (en)	2003-06-24
EP1115701A1 (en)	2001-07-18
CN100335461C (zh)	2007-09-05
NO20011453L (no)	2001-05-23
US6214880B1 (en)	2001-04-10
NO20011453D0 (no)	2001-03-22
BR9913903A (pt)	2001-07-03
CA2343204A1 (en)	2000-03-30
HUP0103884A2 (hu)	2002-05-29
EA200100376A1 (ru)	2001-08-27
PT1115701E (pt)	2003-09-30
KR100642184B1 (ko)	2006-11-10
JP3926983B2 (ja)	2007-06-06
ATE240940T1 (de)	2003-06-15
AU747663B2 (en)	2002-05-16
SK4002001A3 (en)	2001-09-11
KR20010079892A (ko)	2001-08-22
IL142066A (en)	2006-07-05
CN1319088A (zh)	2001-10-24
DK1115701T3 (da)	2003-06-23
HUP0103884A3 (en)	2002-11-28
EP1115701B1 (en)	2003-05-21
WO2000017159A1 (en)	2000-03-30
PL346797A1 (en)	2002-02-25
DE69908156T2 (de)	2003-12-24
CA2343204C (en)	2008-04-29
HK1038913A1 (en)	2002-04-04
AU6058099A (en)	2000-04-10
PL198394B1 (pl)	2008-06-30
US20010027211A1 (en)	2001-10-04
SK284757B6 (sk)	2005-11-03
IL142066A0 (en)	2002-03-10
JP2002526472A (ja)	2002-08-20
DE69908156D1 (de)	2003-06-26
ES2194547T3 (es)	2003-11-16

Publication	Publication Date	Title
ZA200102033B (en)	2001-09-12	Arylsulfonanilide ureas.
EP1401806B1 (en)	2006-08-09	Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
EP1240903A2 (en)	2002-09-18	Combination of calcium (3S) tetrahydro-3-furanyl(1S,2R)-3- [[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy) propylcarbamate with ritonavir
BG64869B1 (bg)	2006-07-31	Сулфонамидни производни,фармацевтични състави и използването им като пролекарства на аспартилпротеазни инхибитори
JP7274765B2 (ja)	2023-05-17	フェニルトリアゾールｍｌｌ１－ｗｄｒ５タンパク質間相互作用阻害剤
AU2007264665B2 (en)	2012-06-14	Potentiator of radiation therapy
CA2561116A1 (en)	2005-10-13	Therapeutic agents, methods, and treatments
CA2380078C (en)	2008-05-06	Combination therapy using pentafluorobenzenesulfonamides
EP0869786B1 (en)	2003-03-05	Pharmaceutical compounds
AU769882B2 (en)	2004-02-05	Medicament containing platinum complex compounds and the use thereof
ZA200402229B (en)	2005-03-22	Reduced toxicity cisplatin formulations and methods for using the same.
EP0658342A1 (en)	1995-06-21	Antineoplastic pharmaceutical composition containing a fumagillol derivative
EP4271667A1 (en)	2023-11-08	Rad51 binding inhibitors and methods of use thereof
CN104250247A (zh)	2014-12-31	新型槐定碱类衍生物槐定酸、槐定醇、槐定酯、槐定醚及其制备方法和用途
KR20050048585A (ko)	2005-05-24	항암 약물용 관능화된 메탈로센
WO1996030024A1 (en)	1996-10-03	The pharmaceutical composition containing the 1,3,2-oxazaphosphorinane and mesna for the cancer treatment
JP2012224592A (ja)	2012-11-15	神経芽細胞腫に対する抗腫瘍薬
EP1285911A2 (en)	2003-02-26	Arylsulfonanilide ureas
GB1045657A (en)	1966-10-12	Dialkylaminoalkyl estrone oxime derivatives
JPH0288524A (ja)	1990-03-28	抗腫瘍剤
CN102459269A (zh)	2012-05-16	嘌呤衍生物以及使用所述嘌呤衍生物的抗肿瘤剂
WO2017034491A1 (en)	2017-03-02	Coordination complexes having anti-cancerogenic and antimicrobial activity